Select

Automatic vision assessment and impairment detection for AMD through Gaze Analysis (AVIGA)

Technology Overview

AVIGA is a platform for an automated, personalized, adaptive, objective, intelligent system for the assessment, detection and monitoring of eyes with macula disease (eg. age-related macular degeneration (AMD)) through gaze analysis. AVIGA consists of a computer based-eye tracking device, our proprietary computer-generatedvisual stimuli test patterns and customised algorithm for analysis of eye gaze movements in response to imagery based visual stimuli. AVIGA selects from a test image gallery and customises a personalized test sequence, in part guided by disease severity as indicated by adjunct tests like fundus imaging or optical coherence tomography. The chosen images will be displayed to the patient adaptively according the detected gaze position. By recording and analysing the gaze, AVIGA is able to generate an objective vision assessment.

Technology Features & Specifications

In this technology, through fundus images of the patient, the severity of the disease is correlated to the test sequence to be used for the eye gaze tests. Very simply, the eye movement is captured in real-timeby commercially available eye gaze tracker with infrared sensors.AVIGA has two assessments, namely, Impulse Stimulus Response (ISR) test and Pursuit Stimulus Response (PSR) test. The data collected from both assessments will be used for Intelligent Functional Vision Analysis (IFVA) to determine the presence of visual impairment in the eye. Depending on the number of algorithms used in this technology, assessment time ranges from 10 - 15 minutes to approximately 1 - 1.5 hours.

Potential Applications

Our proposed system can be used to detect the early symptoms of age related macular degeneration, classify the type of age related macular degeneration, and monitor treatment response on visual function. Our proposed system, a portable disease monitoring device, will enable the detection and monitoring of visual symptoms in age related macular degeneration (AMD) automatically and objectively, with the potential for screening at home or community level.

Customer Benefits

Patients Less tiring for the patient as the patient would not need to focus and artificially fixate on a fixed stationery target throughout the test. More relaxed during the test and this would lead to more accurate results. As the system is non-verbal and based only on visual stimulation and tracking the eye gaze, the results are less subjective and affected by the communication of the patient. Clinicians As the test is fully automatic, without the need for manual instruction, the results of the test are more objective than current methods. The doctors can also rely on the objective results to track the progression of the disease on vision, and also monitor improvements in vision due to rehabilitation or treatment. The fully automatic nature of the test would help to reduce the patient burden on the doctors, as the patients can run the test automatically. Pharmaceutical companies Track the efficacy of drugs through both retinal changes and vision improvements in an objective manner.

Make an Enquiry